Wellness Franchise Opportunities

PharmacySep, 27 2014

Zydus gets USFDA nod to market anti-diabetic tablets

Pharma major Zydus Cadila has received a tentative nod from the US health regulator USFDA to market Glipizide tablets used for the treatment of diabetes in the US.

By WI Bureau

Pharma major Zydus Cadila has received a tentative nod from the US health regulator USFDA to market Glipizide tablets used for the treatment of diabetes in the US.

 

Commenting on the development the company said that Zydus Cadila has received tentative approval from the United States Food and Drug Administration (USFDA) to market Glipizide - extended release tablets in the strengths of 2.5 mg 5 mg and 10 mg.

 

According to IMS Health, the estimated sales in 2014 for Glipizide ER tablets is $90.1 million.

 

The Cadila Healthcare group now has 97 approvals and has so far filed 249 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-2004.

Related: Committed to quality and accessible healthcare services: OPPI

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.


Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.